Batch Manufacturing Record (BMR): Contents, Review, QMS and What Buyers Should Ask

By the PharmaTradz BD Team. Published October 2026.

A batch manufacturing record (BMR) is the completed, signed record of how one specific batch of a medicine was made: which materials went in, which equipment was used, who did each step, what the in-process checks showed and what yield came out. It is filled in from an approved master template while the batch is being made, and it is reviewed by the quality unit before the batch can be released. The batch packaging record (BPR) does the same job for packing and labelling. Together they are the evidence that a batch was made exactly as approved.

The BMR does not stand alone. It sits inside a quality management system (QMS) of written procedures, risk management and yearly product reviews. For a buyer, a supplier's batch records and product reviews are among the most revealing documents you can ask to see.

Master record, executed record and packaging record

Every batch record starts life as a master record. This is the approved template for one product at one batch size. US rules call it the master production and control record (21 CFR 211.186). EU GMP calls it the Manufacturing Formula and Processing Instructions, with separate Packaging Instructions. In everyday use, many companies call it the master formula record (MFR).

Under 21 CFR 211.186, the master record must be prepared, dated and signed by one person and independently checked, dated and signed by a second person.

For each batch, the company issues a controlled copy of the master. Operators fill it in as they work. Once complete, it becomes the executed batch record. US rules call it the batch production and control record (21 CFR 211.188), and EU GMP calls it the Batch Processing Record.

What a batch record must contain

Under 21 CFR 211.188, the batch record starts as an accurate, checked, dated and signed copy of the master. It must then document each significant step, including:

• dates, and the identity of the major equipment and lines used;
• the batch of each component and in-process material, with the weights and measures used;
• in-process and laboratory control results, and any sampling done;
• inspection of the packaging and labelling area before and after use;
• actual yield and the percentage of theoretical yield at the relevant stages;
• labelling control records with specimens of all labelling used, and a description of the containers and closures;
• who performed each significant step and who directly supervised or checked it;
• any investigation made under 21 CFR 211.192.

EU GMP Chapter 4 (Documentation) sets out a very similar list. The Batch Processing Record (4.20) covers the product name and batch number, dates and times, operator initials, the materials weighed, the major equipment used, in-process controls, yields, and any deviations with signed authorisation. The Batch Packaging Record (4.21) adds samples of printed packaging materials showing the batch number and expiry date, and a reconciliation of the printed materials and product used. Our explainer on batch and lot numbers explains how that code links every record together.

A simple worked example

Imagine a master record for a 500 mg tablet at a batch size of 200,000 tablets. It sets a theoretical yield of 200,000 tablets and acceptable limits of 97% to 101% after compression.

On the day, the operator records each weighed material, the balance used and the material batch numbers. A second person checks and signs. The record shows hourly tablet weight and hardness checks. At the end, 195,800 good tablets are counted, a yield of 97.9%. That is inside the limits, so nothing more is needed.

Had the count been 190,000 (95%), the record would show a yield outside limits. Under 21 CFR 211.192, an unexplained discrepancy like this must be thoroughly investigated, even if the batch has already been distributed. In packing, the BPR applies the same logic to printed foil and cartons. Material issued, used, damaged and returned must add up, because a missing roll of printed foil could end up on the wrong product.

Electronic batch records

Many sites now use an electronic batch record (EBR) system. It guides operators step by step and can read weights straight from balances. The content requirements stay the same. What changes is how the record is controlled.

In the US, electronic records and signatures fall under 21 CFR Part 11. In the EU, computerised systems fall under EU GMP Annex 11. Both expect a validated system, secure audit trails, controlled access and reliable electronic signatures. Where automated equipment performs a significant step, 21 CFR 211.188 requires the record to identify the person who checked it. EU GMP Chapter 4 also covers hybrid systems, part paper and part electronic, which need clear controls linking the two.

Whether paper or electronic, entries must be attributable, legible, contemporaneous, original and accurate. Our guide to ALCOA and data integrity explains these principles. Revised drafts of EU GMP Chapter 4 and Annex 11 went to public consultation in 2025, so expect updated wording on electronic records.

Batch record review and release

A batch cannot be released until its records have been reviewed. 21 CFR 211.192 requires the quality control unit to review and approve all production and control records, including packaging and labelling, before a batch is released or distributed. Any unexplained discrepancy or failure must be investigated, and the investigation must extend to other batches that may be affected.

In the EU, a Qualified Person (QP) must certify each batch before release. EU GMP Annex 16, Certification by a Qualified Person and Batch Release, lists what the QP must ensure. This includes that manufacturing records are complete and signed, that the required in-process checks were done, and that deviations and out-of-specification investigations have been dealt with. The QP may rely on the quality system and trained staff for much of this work, but certification is recorded in a register.

Records must also be kept. US rules require batch records to be retained for at least one year after the batch's expiry date (21 CFR 211.180(a)). EU GMP 4.11 requires at least one year after expiry or five years after QP certification, whichever is longer.

SOPs and the quality management system

The BMR tells operators what to do for one product. Standard operating procedures (SOPs) tell them how to do the routine tasks behind it: line clearance, weighing, cleaning, calibration, handling deviations. 21 CFR 211.100 requires written procedures for production and process control. EU GMP 4.29 lists procedures expected for validation, equipment, training, environmental monitoring, complaints, recalls, change control, deviations, internal audits and product quality reviews.

These pieces form the QMS, which pharma guidance calls the pharmaceutical quality system. ICH Q10 Pharmaceutical Quality System describes four elements:

• process performance and product quality monitoring;
• corrective and preventive action (CAPA);
• change management;
• management review of process performance and product quality.

ICH Q10 names knowledge management and quality risk management as the two enablers. In practice, the batch record feeds every element. Its yields and test results feed monitoring, its deviations feed CAPA, and changes to the master record go through change control.

Quality risk management under ICH Q9(R1)

ICH Q9(R1) Quality Risk Management, adopted in January 2023, defines risk as the combination of the probability of harm and its severity. It sets two principles. Risk evaluation should rest on scientific knowledge and link to patient protection. The effort, formality and documentation should match the level of risk.

The process runs through risk assessment (identification, analysis, evaluation), risk control (reduction and acceptance), risk communication and risk review. Tools include failure mode and effects analysis (FMEA), hazard analysis and critical control points (HACCP) and risk ranking. The R1 revision added guidance on formality, subjectivity, risk-based decision-making and risks to product availability.

For batch records, QRM decides which steps are critical and need a second-person check. It also decides how far a deviation investigation must reach and what the QP weighs when a batch has an unexpected deviation.

Annual product review and product quality review

Once a year, the manufacturer reviews each product as a whole. In the US this is the annual product review (APR). Under 21 CFR 211.180(e), records must be evaluated at least annually to decide whether specifications or manufacturing or control procedures need to change. The review must cover a representative number of batches, approved or rejected, plus complaints, recalls, returned or salvaged products and investigations.

In the EU it is the product quality review (PQR) under EU GMP Chapter 1, section 1.10. It is normally done annually and reviews starting and packaging materials, critical in-process controls and results, failed batches, significant deviations, changes, variations, stability results, complaints and recalls, and the qualification status of equipment and utilities. Many companies combine the two as an annual product quality review (APQR).

The PQR is where trends show up: a yield that is slowly falling, or stability results creeping towards the limit. A good PQR names the trend and the action taken.

What buyers should ask to see

Most manufacturers will share redacted extracts or show batch records during an audit. Useful requests include:

• An executed BMR and BPR extract for a validation batch, ideally one of the process validation batches behind your product. Check that signatures, dates, yields and reconciliations are complete and that corrections are signed and readable. Our guide to IQ, OQ, PQ and process validation explains what those batches prove.
• The master record's index and version history, to confirm the batch size and process match the registered dossier.
• The latest PQR or APR summary for the product: number of batches, rejected batches, deviations, OOS results, complaints and stability trends.
• The SOP list for batch record issue, review and release, and how the QA or QP review is documented.
• EBR or hybrid system status: whether the system is validated and how audit trails are reviewed.
• A recent risk assessment under ICH Q9(R1), for example on a process change or a new supplier.

Red flags include identical handwriting across operators, entries that look filled in after the event, missing reconciliations and PQRs that report no deviations at all. Our guide to verifying a pharmaceutical supplier covers the wider checks.

How PharmaTradz can help

Our documentation and quality pack gathers key quality documents from manufacturers before you commit, including PQR summaries and redacted batch record extracts where suppliers agree to share them. Tell us the product, market and documents you need, and send us an RFQ. For other terms, see our pharma abbreviations A-Z.

Frequently Asked Questions(FAQs)

What is a BMR in pharma?

BMR stands for batch manufacturing record: the completed, signed record of how one batch of a medicine was made, filled in from an approved master template and reviewed by the quality unit before the batch is released.

What is the difference between a BMR and a BPR?

The BMR records the manufacture of a batch, from weighing to the finished bulk product. The BPR (batch packaging record) records how that batch was packed and labelled, including samples of printed materials and a reconciliation of what was used.

What is the difference between an MFR and a BMR?

The MFR (master formula record) is the approved template for a product at one batch size. The BMR is the copy of it that is filled in and signed for one specific batch.

What are the four elements of a QMS under ICH Q10?

Process performance and product quality monitoring, corrective and preventive action (CAPA), change management, and management review. Knowledge management and quality risk management support all four.

What is quality risk management in pharma?

Under ICH Q9(R1), it is a systematic process for assessing, controlling, communicating and reviewing risks to product quality across the product's lifecycle. The effort and formality should match the level of risk.